KMTS Earnings

KMTS reported its earnings on 2025-12-11, showcasing a revenue of 22.57M against an estimate of 21.22M, resulting in a 6.35% surprise. The EPS was -0.64, surpassing the expected -0.56 by -14.29% . The stock experienced a 5.06% price change on the earnings day and a 7.67% change over the next five days, reflecting market reactions to the results.

Following KMTS's earnings announcement on 2025-12-11, the stock price moved by 5.06% on the day of the release. Over the subsequent five days, it saw a 7.67% change. Historically, KMTS's stock price tends to shift by an average of +3.14% in the 10 days leading up to earnings and +11.03% in the 10 days following, providing insight into potential market.

For , analysts estimate KMTS’s annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 3.35% and EPS estimates Revise Upward by 3.57% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between KMTS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 3.35%, while EPS estimates moved Revise Upward by 3.57% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, KMTS's stock price typically moves by +3.14% in the 10 days before its earnings and +11.03% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call reveals strong revenue growth, market expansion, and a strategic focus on innovation. Despite increased losses, cash reserves are robust. The Q&A highlights sustainable growth strategies and positive market reaction to clinical data. The company's guidance and strategic plans suggest a positive outlook, with expected gross margin expansion and increased prescription volumes. While there are uncertainties regarding guideline changes, the overall sentiment is positive, driven by strong financial metrics and optimistic guidance, likely leading to a stock price increase in the short term.